- Condition
- Hashimoto's Thyroiditis
- Patient profile
- F, age band 35–44, Canada
- Outcome scale
- anti-TPO (lower is better)
Twelve-month tracking of anti-TPO antibody levels and TSH for a Canadian patient with Hashimoto's thyroiditis following a Wharton's Jelly MSC autoimmune protocol in Istanbul.
Antibody decline is a surrogate marker, not a clinical endpoint. Hashimoto's progression and remission patterns are heterogeneous. This case is one patient's experience and is not a predictor of any other patient's outcome.
anti-TPO timeline
Anti-TPO antibody titre is a serological marker for autoimmune thyroiditis. Levels above ~35 IU/mL are typically considered positive. Antibody decline does not by itself prove disease modification but is a tracked surrogate marker.
| Timepoint | anti-TPO | Δ vs baseline |
|---|---|---|
| Baseline | 612 | — |
| Day 90 | 488 | -124 |
| Day 180 | 341 | -271 |
| Day 365 | 287 | -325 |
Hashimoto's thyroiditis on stable levothyroxine replacement, 7 years since diagnosis. Persistent fatigue and cold intolerance despite euthyroid TSH. Baseline anti-TPO 612 IU/mL.
Intravenous Wharton's Jelly MSCs across two infusions, structured autoimmune workup including thyroid panel (TSH, free T4, free T3), anti-TPO, anti-TG, hsCRP, ESR, vitamin D and B12. Levothyroxine continued at baseline dose with home endocrinology oversight.
Anti-TPO re-tested at Days 90, 180 and 365 by the home endocrinologist. TSH remained within reference range throughout. Patient self-reported reduced fatigue at Day 90 and improved cold tolerance at Day 180.
None reported through Day 365.